David J Kuter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6154527/publications.pdf

Version: 2024-02-01

166 papers	9,714 citations	57631 44 h-index	38300 95 g-index
190 all docs	190 docs citations	190 times ranked	7761 citing authors

#	Article	IF	Citations
1	SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood, 2022, 139, 1564-1574.	0.6	55
2	Novel therapies for immune thrombocytopenia. British Journal of Haematology, 2022, 196, 1311-1328.	1.2	19
3	Efficacy and safety of givosiran for acute hepatic porphyria: 24â€month interim analysis of the randomized phase 3 ENVISION study. Liver International, 2022, 42, 161-172.	1.9	41
4	The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Reviews, 2022, 53, 100909.	2.8	21
5	Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results. Haematologica, 2022, 107, 1698-1702.	1.7	18
6	Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, openâ€label study. American Journal of Hematology, 2022, 97, 691-699.	2.0	19
7	Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. New England Journal of Medicine, 2022, 386, 1421-1431.	13.9	52
8	An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica, 2021, 106, 2161-2169.	1.7	64
9	A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica, 2021, 106, 1148-1157.	1.7	49
10	An evaluation of avatrombopag for the treatment of thrombocytopenia. Expert Opinion on Pharmacotherapy, 2021, 22, 273-280.	0.9	19
11	Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria. American Journal of Hematology, 2021, 96, E235-E237.	2.0	4
12	How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. Blood, 2021, 137, 2736-2744.	0.6	15
13	Exacerbation of immune thrombocytopenia following COVIDâ€19 vaccination. British Journal of Haematology, 2021, 195, 365-370.	1.2	72
14	Lessons Learned Using Realâ€World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia. Clinical Pharmacology and Therapeutics, 2021, 110, 1570-1578.	2.3	2
15	Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. Blood Reviews, 2021, 49, 100811.	2.8	9
16	Thrombopoietin level predicts response to treatment with romiplostim in chemotherapyâ€induced thrombocytopenia. American Journal of Hematology, 2021, 96, 1563-1568.	2.0	6
17	Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study). Blood, 2021, 138, 2088-2088.	0.6	3
18	Thrombopoietin Level Predicts Response to Treatment with Romiplostim in Chemotherapy-Induced Thrombocytopenia. Blood, 2021, 138, 584-584.	0.6	0

#	Article	IF	Citations
19	Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia. Blood, 2021, 138, 14-14.	0.6	5
20	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. Blood, 2021, 138, 586-586.	0.6	1
21	LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia. Blood, 2021, 138, 1010-1010.	0.6	5
22	Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 219-225.	0.2	13
23	Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. Bone Marrow Transplantation, 2020, 55, 1178-1180.	1.3	2
24	Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. Seminars in Thrombosis and Hemostasis, 2020, 46, 275-288.	1.5	49
25	Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. American Journal of Hematology, 2020, 95, 178-187.	2.0	99
26	Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Reviews, 2020, 41, 100648.	2.8	267
27	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leukemia Research, 2020, 98, 106459.	0.4	16
28	Scoring system to facilitate diagnosis of Gaucher disease. Internal Medicine Journal, 2020, 50, 1538-1546.	0.5	9
29	Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Expert Review of Hematology, 2020, 13, 1319-1332.	1.0	10
30	Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (<scp>COVID</scp>â€19). American Journal of Hematology, 2020, 95, 1479-1485.	2.0	24
31	Preparing patients with immune thrombocytopenia for surgery: what are the options?. Lancet Haematology,the, 2020, 7, e626-e627.	2.2	2
32	Case 38-2020: A 52-Year-Old Man with Cancer and Acute Hypoxemia. New England Journal of Medicine, 2020, 383, 2372-2383.	13.9	4
33	The role of romiplostim for pediatric patients with immune thrombocytopenia. Therapeutic Advances in Hematology, 2020, 11, 204062072091299.	1.1	19
34	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, 2020, 136, 489-500.	0.6	1,021
35	Congenital thrombotic thrombocytopenic purpura (TTP) with placental abruption despite maternal improvement: a case report. BMC Pregnancy and Childbirth, 2020, 20, 365.	0.9	2
36	Safety and efficacy of selfâ€administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. American Journal of Hematology, 2020, 95, 643-651.	2.0	14

#	Article	IF	Citations
37	Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia. American Journal of Hematology, 2020, 95, 1180-1186.	2.0	26
38	Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia. Clinical and Translational Gastroenterology, 2020, 11, e00118.	1.3	3
39	Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. British Journal of Haematology, 2020, 190, 923-932.	1.2	12
40	Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy. Blood Cells, Molecules, and Diseases, 2020, 82, 102418.	0.6	4
41	A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Advances, 2020, 4, 9-18.	2.5	56
42	Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the Envision Open Label Extension. Blood, 2020, 136, 13-13.	0.6	4
43	Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia. Blood, 2020, 136, 13-14.	0.6	6
44	Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia. Blood, 2020, 136, 14-15.	0.6	13
45	Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study. Blood, 2020, 136, 1-3.	0.6	4
46	Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress. Blood, 2020, 136, 6-7.	0.6	0
47	Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations. Blood, 2020, 136, 29-29.	0.6	0
48	Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19. Blood, 2020, 136, 4-5.	0.6	0
49	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up. Blood, 2020, 136, 24-25.	0.6	3
50	Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 579-584.e1.	0.2	16
51	Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. British Journal of Haematology, 2019, 187, e61-e64.	1.2	6
52	Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Therapeutic Advances in Hematology, 2019, 10, 204062071984173.	1.1	65
53	Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease. International Journal of Laboratory Hematology, 2019, 41, 325-330.	0.7	0
54	Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (<scp>ITP</scp>) for up to 1Âyear and in those with chronic <scp>ITP</scp> for more than 1Âyear: a subgroup analysis of integrated data from completed romiplostim studies. British Journal of Haematology, 2019, 185, 503-513.	1.2	49

#	Article	IF	Citations
55	Recurrence of Acute Intermittent Porphyria After Liver Transplantation. Annals of Internal Medicine, 2019, 170, 904.	2.0	9
56	Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance. Blood Advances, 2019, 3, 3515-3521.	2.5	24
57	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advances, 2019, 3, 3780-3817.	2.5	593
58	American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, 3, 3829-3866.	2.5	684
59	Presenting signs and patient coâ€variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GEDâ€C) Delphi initiative. Internal Medicine Journal, 2019, 49, 578-591.	0.5	39
60	Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. Annals of Hematology, 2019, 98, 581-588.	0.8	34
61	Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. American Journal of Hematology, 2019, 94, 149-161.	2.0	55
62	General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors. , 2019, , 108-126.		6
63	Inhibition of the Classical Pathway of Complement with Sutimlimab in Chronic Immune Thrombocytopenic Purpura Patients without Adequate Response to Two or More Prior Therapies. Blood, 2019, 134, 898-898.	0.6	6
64	Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia. Blood, 2019, 134, 87-87.	0.6	12
65	Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study. Blood, 2019, 134, 3518-3518.	0.6	3
66	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. Blood, 2019, 134, 4172-4172.	0.6	6
67	Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia. Blood, 2019, 134, 895-895.	0.6	1
68	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study. Blood, 2019, 134, LBA-2-LBA-2.	0.6	9
69	An International Multicenter Study of Intravenous Bevacizumab for the Treatment of Chronic Bleeding and Anemia in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bleed Study. Blood, 2019, 134, 1060-1060.	0.6	0
70	Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia. Blood, 2019, 134, 4800-4800.	0.6	0
71	Hepatocellular carcinoma in Gaucher disease: an international case series. Journal of Inherited Metabolic Disease, 2018, 41, 819-827.	1.7	37
72	The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica, 2018, 103, e169-e172.	1.7	51

#	Article	IF	Citations
73	Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma. Medicine (United States), 2018, 97, e13321.	0.4	8
74	Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations. Haematologica, 2018, 103, e492-e495.	1.7	6
75	Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. American Journal of Hematology, 2018, 93, 1501-1508.	2.0	55
76	Avatrombopag, an oral thrombopoietin receptor agonist: results of two doubleâ€blind, doseâ€rising, placeboâ€controlled Phase 1 studies. British Journal of Haematology, 2018, 183, 466-478.	1.2	22
77	Romiplostim for the management of perioperative thrombocytopenia. British Journal of Haematology, 2018, 182, 106-113.	1.2	37
78	Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologistâ€™s perspective. Haematologica, 2018, 103, 1433-1443.	1.7	123
79	Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. British Journal of Haematology, 2018, 183, 168-168.	1.2	26
80	An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. British Journal of Clinical Pharmacology, 2018, 84, 2673-2677.	1.1	24
81	Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study. Blood, 2018, 132, 3612-3612.	0.6	6
82	Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database. Blood, 2018, 132, 3284-3284.	0.6	1
83	Assessment of Romiplostim Immunogenicity in Adult Patients in Clinical Trials and in a Global Registry. Blood, 2018, 132, 2427-2427.	0.6	3
84	Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials. Blood, 2018, 132, 3740-3740.	0.6	1
85	Antiplatelet Antibody Testing in Immune Thrombocytopenia and Evans Syndrome: Longitudinal Serologic Evolution and Relation to Clinical Features. Blood, 2018, 132, 1137-1137.	0.6	5
86	Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study. Blood, 2018, 132, 3285-3285.	0.6	0
87	Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy. Blood, 2018, 132, 3755-3755.	0.6	0
88	Systemic Bevacizumab for the Treatment of Chronic Bleeding in Hereditary Hemorrhagic Telangiectasia. Blood, 2018, 132, 852-852.	0.6	0
89	Thrombopoietin Level Predicts Response to Treatment with Eltrombopag and Romiplostim in Immune Thrombocytopenia. Blood, 2018, 132, 734-734.	0.6	1
90	Clinical outcomes in a cohort of patients with heparinâ€induced thrombocytopenia. American Journal of Hematology, 2017, 92, 730-738.	2.0	49

#	Article	IF	Citations
91	Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Molecular Genetics and Metabolism, 2017, 122, 122-129.	0.5	51
92	Pure White Cell Aplasia and Necrotizing Myositis. Case Reports in Hematology, 2016, 2016, 1-5.	0.3	4
93	What is the role of novel thrombopoietic agents in the management of acute leukemia?. Best Practice and Research in Clinical Haematology, 2016, 29, 372-378.	0.7	5
94	Remissions after long-term use of romiplostim for immune thrombocytopenia. Haematologica, 2016, 101, e476-e478.	1.7	21
95	Markers of Autoimmunity in Immune Thrombocytopenia: Prevalence and Prognostic Significance. Blood, 2016, 128, 1363-1363.	0.6	1
96	Romiplostim for Treatment and Prevention of Chemotherapy-Associated Thrombocytopenia. Blood, 2016, 128, 3748-3748.	0.6	2
97	Key Presenting Signs and Patient Co-Variables in Early Diagnosis of Type 3 Gaucher Disease: A Global Delphi Consensus Initiative. Blood, 2016, 128, 4886-4886.	0.6	1
98	Safety and Efficacy of PRTX-100, a Highly Purified Form of Staphylococcal Protein A, in Patients with Immune Thrombocytopenia (ITP). Blood, 2016, 128, 4929-4929.	0.6	7
99	Health care resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): Results from PREAMBLE.. Journal of Clinical Oncology, 2016, 34, 6621-6621.	0.8	1
100	A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Key Presenting Signs and Patient Co-Variables in Type 1 Disease. Blood, 2016, 128, 3676-3676.	0.6	0
101	A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Barriers, Their Resolution and the Impact on Patients. Blood, 2016, 128, 4885-4885.	0.6	0
102	An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy. Blood, 2016, 128, 2403-2403.	0.6	5
103	FF-10102-01: A Novel, Highly Selective Spleen Tyrosine Kinase Inhibitor, to Be in Clinical Application for Treatment of Autoimmune Diseases and B-Cell Malignancies. Blood, 2016, 128, 3745-3745.	0.6	0
104	Romiplostim in the management of the thrombocytopenic surgical patient. Transfusion, 2015, 55, 2505-2510.	0.8	24
105	Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. International Journal of Hematology, 2015, 101, 255-263.	0.7	49
106	An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival. Blood, 2015, 126, 2093-2093.	0.6	1
107	Milestones in understanding platelet production: a historical overview. British Journal of Haematology, 2014, 165, 248-258.	1.2	85
108	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood, 2014, 123, 3887-3894.	0.6	112

#	Article	IF	Citations
109	TPO concentrations and response to romiplostim. American Journal of Hematology, 2014, 89, 1155-1156.	2.0	11
110	Romiplostim in Management of the Thrombocytopenic Surgical Patient. Blood, 2014, 124, 1459-1459.	0.6	0
111	The biology of thrombopoietin and thrombopoietin receptor agonists. International Journal of Hematology, 2013, 98, 10-23.	0.7	197
112	Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells, Molecules, and Diseases, 2013, 51, 116-124.	0.6	60
113	Longâ€term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology, 2013, 161, 411-423.	1.2	234
114	Thrombopoietin levels in patients with disorders of platelet production: Diagnostic potential and utility in predicting response to TPO Receptor agonists. American Journal of Hematology, 2013, 88, 1041-1044.	2.0	70
115	Healthâ€related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. American Journal of Hematology, 2012, 87, 558-561.	2.0	68
116	What is the potential for thrombopoietic agents in acute leukemia?. Best Practice and Research in Clinical Haematology, 2011, 24, 553-558.	0.7	10
117	Thrombopoietin Levels May Predict Responsiveness to Therapy with Thrombopoietin Agonists Among Patients with Immune Thrombocytopenic Purpura,. Blood, 2011, 118, 3288-3288.	0.6	4
118	Patient Reported Outcomes Comparison of Chronic Immune Thrombocytopenia (ITP) Patients Switched to Promacta and Nplate. Blood, 2011, 118, 2220-2220.	0.6	0
119	Miglustat Therapy in Type 1 Gaucher Disease: Long-Term Treatment Experience From a Multicenter, Retrospective Cohort Study,. Blood, 2011, 118, 3207-3207.	0.6	0
120	A Double-Blind, Placebo-Controlled, and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ono-7746 in Healthy Subjects. Blood, 2011, 118, 4828-4828.	0.6	0
121	Single Oral Doses of a Novel Thrombopoietin Mimetic ONO-7746 Increase Platelet Counts In Healthy Subjects. Blood, 2011, 118, 4827-4827.	0.6	0
122	Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. New England Journal of Medicine, 2010, 363, 1889-1899.	13.9	374
123	Biology and Chemistry of Thrombopoietic Agents. Seminars in Hematology, 2010, 47, 243-248.	1.8	93
124	Romiplostim. Cancer Treatment and Research, 2010, 157, 267-288.	0.2	28
125	Efficacy, Safety and Tolerability of E5501 (AKR501) In a 6-Month Extension Study In Subjects with Chronic Immune Thrombocytopenia (ITP).. Blood, 2010, 116, 3695-3695.	0.6	4
126	Analysis of Mortality Rates During Romiplostim Clinical Studies of Patients (Pts) with Immune Thrombocytopenia (ITP).. Blood, 2010, 116, 3701-3701.	0.6	5

#	Article	IF	Citations
127	Patient Quality of Life (QOL) In Nonsplenectomized Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim or Medical Standard of Care (SOC). Blood, 2010, 116, 569-569.	0.6	1
128	Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study. Blood, 2010, 116, 68-68.	0.6	15
129	A Randomized, Double-Blind, Placebo-Controlled Phase II Trial on the Efficacy, Safety and Tolerability of E5501 (AKR501) In Subjects with Chronic Immune Thrombocytopenia (ITP). Blood, 2010, 116, 71-71.	0.6	8
130	The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.. Blood, 2010, 116, 3702-3702.	0.6	0
131	Thrombin Generation During Abdominal Surgical Procedures: Effect of Prophylactic Anticoagulation Therapy. Blood, 2010, 116, 3183-3183.	0.6	0
132	Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood, 2009, 114, 3748-3756.	0.6	177
133	New Thrombopoietic Growth Factors. Clinical Lymphoma and Myeloma, 2009, 9, S347-S356.	1.4	95
134	Thrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia. Annual Review of Medicine, 2009, 60, 193-206.	5.0	164
135	Thrombopoietin and Platelet Production in Chronic Immune Thrombocytopenia. Hematology/Oncology Clinics of North America, 2009, 23, 1193-1211.	0.9	60
136	Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.. Blood, 2009, 114, 679-679.	0.6	4
137	Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.. Blood, 2009, 114, 681-681.	0.6	4
138	New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. European Journal of Haematology, 2008, 80, 9-18.	1.1	38
139	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, The, 2008, 371, 395-403.	6.3	784
140	Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study. Blood, 2008, 112, 402-402.	0.6	10
141	Gestational Platelet Trends and Outcomes in Women with Myeloproliferative Disorders Characterized by Thrombocytosis. Blood, 2008, 112, 5251-5251.	0.6	0
142	New thrombopoietic growth factors. Blood, 2007, 109, 4607-4616.	0.6	312
143	Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. British Journal of Haematology, 2007, 139, 351-362.	1.2	249
144	A Comparative Proteomic Analysis of Platelets from Healthy Human Patients and Chronic ITP Patients Receiving AMG 531, a Thrombopoiesis-Stimulating Protein.. Blood, 2007, 110, 1313-1313.	0.6	2

#	Article	IF	Citations
145	The Incidence of Thrombosis in Patients with Isolated Heparin Induced Thrombocytopenia.. Blood, 2006, 108, 1049-1049.	0.6	2
146	Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.. Blood, 2006, 108, 3982-3982.	0.6	18
147	The Identification of Hypercoagulable Markers in Patients with Malignant Gliomas and Venous Thromboembolism.. Blood, 2006, 108, 4097-4097.	0.6	1
148	Long-Term Follow-Up of Monoclonal Gammopathies in Gaucher Disease Patients on Enzyme Replacement Therapy.. Blood, 2006, 108, 3336-3336.	0.6	0
149	Thrombotic Complications of Central Venous Catheters in Cancer Patients. Oncologist, 2004, 9, 207-216.	1.9	213
150	In Reply: Lowâ€Dose Warfarin Prophylaxis for Catheterâ€Associated Thrombosis in Cancer Patients. Can It Be Safely Associated with 5â€Fluorouracilâ€Based Chemotherapy?. Oncologist, 2004, 9, 596-596.	1.9	3
151	Fondaparinux in the Treatment of Heparin-Induced Thrombocytopenia.. Blood, 2004, 104, 1775-1775.	0.6	23
152	Phase II Trial of Single Agent Bortezomib (VELCADEÂ®) in Patients with Previously Untreated Multiple Myeloma (MM).. Blood, 2004, 104, 336-336.	0.6	36
153	Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood, 2002, 100, 3457-3469.	0.6	351
154	Apoptosis in Platelets During Ex Vivo Storage. Vox Sanguinis, 2002, 83, 311-313.	0.7	21
155	Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood, 2001, 98, 3241-3248.	0.6	658
156	Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood, 2001, 98, 1339-1345.	0.6	89
157	The End Is Just the Beginning: Megakaryocyte Apoptosis and Platelet Release. International Journal of Hematology, 2001, 74, 365-374.	0.7	45
158	The mechanism of apoptosis in human platelets during storage. Transfusion, 2000, 40, 1320-1329.	0.8	156
159	The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. British Journal of Haematology, 2000, 111, 943-953.	1.2	27
160	Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. British Journal of Haematology, 1999, 106, 345-356.	1.2	147
161	Cancer, Coagulation, and Anticoagulation. Oncologist, 1999, 4, 443-449.	1.9	48
162	Apheresis platelets: Emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. Journal of Clinical Apheresis, 1998, 13, 114-119.	0.7	31

#	Article	IF	Citations
163	The use of PEG‐rHuMGDF in platelet apheresis. Stem Cells, 1998, 16, 231-242.	1.4	19
164	Apheresis platelets: Emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. , 1998, 13, 114.		3
165	The Physiology of Platelet Production. Stem Cells, 1996, 14, 88-101.	1.4	111
166	Thrombopoietin: Biology and Clinical Applications. Oncologist, 1996, 1, 98-106.	1.9	29